Effect of OKN-007 on the immunoexpression of decorin in IC3752 pGBM tumor bearing mice. by Patricia Coutinho de Souza (780490)

Doxorubicin (DOXO) decreases STMN1 and increases TTP in HTR-8 cells. by Xiao-Ling Ma (4179232)

Claudin-18 knockdown by siRNA. (A) Claudin-18 siRNA significantly decreases the mRNA level of claudin-18 in MKN74. by Tadayuki Oshima (461127)

Mutation of stathmin phosphorylation sites decreases sensitivity to bortezomib and influences tubulin polymerization. by Feng Ge (64593)

Fibrinogen decreases cardiomyocyte contractility through an ICAM-1-dependent mechanism-2 by John H Boyd (88940)

Decreased bacterial burden in mice with T-cell targeted deletion of HIF-1 α. by Manfred Thiel (310810)

Table 1_A novel α-conotoxin [D1G, ΔQ14] LvIC decreased mouse locomotor activity.xls by Wen Wang (6570)

Effect of OKN-007 on diffusion measured as ADC values in IC3752 pGBM tumor bearing mice. by Patricia Coutinho de Souza (780490)

Treatment with proteasome inhibitor bortezomib decreases organic anion transporting polypeptide (OATP) 1B3-mediated transport in a substrate-dependent manner by Khondoker Alam (1443499)

“…Pretreatment with bortezomib (50–250 nM, 2–7 h) significantly decreased transport of [³H]CCK-8, a specific OATP1B3 substrate, in HEK293-OATP1B3 and human sandwich-cultured hepatocytes (SCH). …”

Effect of OKN-007 on perfusion rates measured as rCBF in IC3752 pGBM tumor bearing mice. by Patricia Coutinho de Souza (780490)

Effect of OKN-007 on the immunoexpression of SULF2 in IC3752 pGBM tumor bearing mice. by Patricia Coutinho de Souza (780490)

“…OKN-007 (NR); (4) Normal vs. OKN-007 (R); (5) UT vs. OKN-007 (NR); and (6) Normal vs. OKN-007 (NR).…”

Effect of OKN-007 on the immunoexpression of PDGFR-α in IC3752 pGBM tumor bearing mice. by Patricia Coutinho de Souza (780490)

“…OKN-007 (NR); (4) Normal vs. OKN-007 (R); (5) UT vs. OKN-007 (NR); and (6) Normal vs. OKN-007 (NR).…”

Bcl-xL protein levels were decreased in response to siRNA transfection in A549, SK-LU1 and NP-69 cells. by Norahayu Othman (495150)

“…<p>(<b>A</b>) Western blot indicating a significant decrease in Bcl-xL protein levels in comparison to non-transfected cells 48 h post-transfection. …”

SIRT1-mediated CRIF1 deletion-induced inflammatory cytokine and VCAM-1 expression. by Shuyu Piao (4731327)

File S1 - S-Nitrosoglutathione Accelerates Recovery from 5-Fluorouracil-Induced Oral Mucositis by Maria Adriana Skeff (670466)

(A) The proportion of fast MyHC myotubes is decreased in Igf-2 deficient mice (maternal disomy Chromosome 7 - MatDi) at E14 by Deborah Merrick (54928)

“…<p><b>Copyright information:</b></p><p>Taken from "A role for Insulin-like growth factor 2 in specification of the fast skeletal muscle fibre"</p><p>http://www.biomedcentral.com/1471-213X/7/65</p><p>BMC Developmental Biology 2007;7():65-65.…”

Morphometric data of layer II/III and V/VI pyramidal neurons. by Janine R. Neumann (6330863)

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”